Cargando…
Cost-utility analysis of adjuvant imatinib treatment in patients with high risk of recurrence after gastrointestinal stromal tumour (GIST) resection in Thailand
BACKGROUND: Many patients develop tumour recurrence within a few years after undergoing surgical resection of gastrointestinal stromal tumours (GIST). Adjuvant imatinib treatment is recommended for patients with high risk of GIST recurrence as it can improve recurrence-free survival and overall surv...
Autores principales: | Bussabawalai, Thanaporn, Thiboonboon, Kittiphong, Teerawattananon, Yot |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323771/ https://www.ncbi.nlm.nih.gov/pubmed/30636935 http://dx.doi.org/10.1186/s12962-018-0169-9 |
Ejemplares similares
-
Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010) -
An economic analysis of chromosome testing in couples with children who have structural chromosome abnormalities
por: Thiboonboon, Kittiphong, et al.
Publicado: (2018) -
Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST)
por: Nilsson, B, et al.
Publicado: (2007) -
Laparoscopic resection of locally advanced gastrointestinal stromal tumour (GIST) of the stomach following neoadjuvant imatinib chemoreduction
por: Berney, Christophe R.
Publicado: (2015) -
Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients
por: Bümming, P, et al.
Publicado: (2003)